Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.71 |
| ▸ | PRKCG | P05129 | 4/20 | 0.71 |
| ▸ | PRKCB | P05771 | 4/20 | 0.71 |
| ▸ | PRKCH | P24723 | 4/20 | 0.71 |
| ▸ | PRKCI | P41743 | 4/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.71 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.71 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21981002 | 1.00 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL18628313 | 1.00 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL15423138 | 1.00 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL18399929 | 1.00 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL16922842 | 1.00 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL30194475 | 1.00 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| Ammonia Solution, Strong SCHEMBL5508975 | 0.99 | PRKCA (0.70) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL12925016 | 0.93 | PRKCA (0.65) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL18399927 | 0.93 | PTGS2 (0.64) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL15423106 | 0.93 | PTGS2 (0.64) | PRKCAPRKD3PRKCGPRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 582 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| US-12539289-B2 | Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia | BIOSUCCESS BIOTECH COMPANY, LIMITED (US) | 2026-02-03 | — | — | US | claimed |
| EP-2804601-B1 | PHORBOL ESTER compounds for use in the treatment of neoplastic diseases | BIOSUCCESS BIOTECH CO LTD (US) | 2025-04-02 | — | — | EP | claimed |
| US-20240261247-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | BIOSUCCESS BIOTECH CO., LTD. (US) | 2024-08-08 | — | — | US | claimed |
| US-20240082202-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2024-03-14 | — | — | US | claimed |
| EP-4304570-A2 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES | Phor-Med, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117015375-A | Compositions and methods for treating Acute Respiratory Distress Syndrome (ARDS) and inflammatory conditions caused by coronaviruses | 福尔医学公司 | 2023-11-07 | — | — | CN | claimed |
| US-20230277495-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | BIOSUCCESS BIOTECH CO. LTD. (US) | 2023-09-07 | — | — | US | claimed |
| US-20230248684-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES AND OTHER RESPIRATORY PATHOGENS OR AGENTS THAT MEDIATE PULMONARY INJURY, INFLAMMATION OR ACUTE RESPIRATORY DISTRESS, AND RELATED COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN SARS CORONAVIRUS INFECTION, COVID-19 DISEASE AND RELATED SYMPTOMS | PHOR-MED, INC. | 2023-08-10 | — | — | US | claimed |
| US-11696908-B2 | Compositions and methods of use of phorbol esters | BIOSUCCESS BIOTECH CO. LTD. (US) | 2023-07-11 | — | — | US | claimed |
| WO-2013110006-A2 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | BIOSUCCESS BIOTECH CO. LTD. (US) | 2013-07-25 | — | — | WO | claimed |
| EP-2368555-A1 | Compositions and methods of use of phorbolesters | Biosuccess Biotech Company (US) | 2011-09-28 | — | — | EP | claimed |
| EP-2170053-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | Biosuccess Biotech Company (US) | 2010-04-07 | — | — | EP | claimed |
| US-20080226589-A1 | Such as phorbol 13-butyrate for treatment of cytopathic diseases such as HIV, AIDS, and/or neoplasms | BIOSUCCESS BIOTECH CO. | 2008-09-18 | — | — | US | claimed |
| WO-2008094657-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | BIOSUCCESS BIOTECH COMPANY (US) | 2008-08-07 | — | — | WO | claimed |
| EP-0349127-B1 | ANTIBODY-MEDIATED AND LIGAND-MEDIATED TARGETING OF DIFFERENTIATION-INDUCERS TO TUMOR CELLS | The Biomembrane Institute (US) | 1993-09-29 | — | — | EP | claimed |
| EP-0108919-B1 | PROCESS FOR PRODUCING T CELL-ACTIVATING FACTOR | Okai, Yasuji (JP) | 1988-07-13 | — | — | EP | claimed |
| US-4613458-A | INHIBITS DNA SYNEHESIS OF T CELLS, AUTOIMMUNE DISEASES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1986-09-23 | — | — | US | claimed |
| EP-0135592-A1 | DNA SYNTHESIS-REPRESSING SUBSTANCE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1985-04-03 | — | — | EP | claimed |
| EP-0108919-A2 | Process for producing T cell-activating factor | Okai, Yasuji (JP) | 1984-05-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696908-B2 | Compositions and methods of use of phorbol esters | PMAIP1, CD38, PKD1 | PRKCA 41/4885PRKD3 229/4885PRKCG 53/4885 |
| US-20240261247-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | PMAIP1, KLK3, ACP3 | PRKCA 42/4885PRKD3 235/4885PRKCG 51/4885 |
| US-20230277495-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | PMAIP1, KLK3, ACP3 | PRKCA 42/4885PRKD3 235/4885PRKCG 51/4885 |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | TSLP, MAVS, PLAA | PRKCA 32/4885PRKD3 910/4885PRKCG 102/4885 |
| US-20080226589-A1 | Such as phorbol 13-butyrate for treatment of cytopathic diseases such as HIV, AIDS, and/or neoplasms | STAT6, NFATC1, BAD | PRKCA 164/4885PRKD3 138/4885PRKCG 366/4885 |
| US-12539289-B2 | Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia | MYD88, EBP, IL2 | PRKCA 45/4885PRKD3 274/4885PRKCG 154/4885 |
| US-20240082202-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | MAVS, ACE2, PLAA | PRKCA 12/4885PRKD3 885/4885PRKCG 36/4885 |
| US-20230248684-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES AND OTHER RESPIRATORY PATHOGENS OR AGENTS THAT MEDIATE PULMONARY INJURY, INFLAMMATION OR ACUTE RESPIRATORY DISTRESS, AND RELATED COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN SARS CORONAVIRUS INFECTION, COVID-19 DISEASE AND RELATED SYMPTOMS | MAVS, ACE2, CCL11 | PRKCA 16/4885PRKD3 716/4885PRKCG 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.